Total Payments
$1,077
2024 Payments
$156.03
Companies
13
Transactions
52
Medicare Patients
2,968
Medicare Billing
$420,571
Payment Breakdown by Category
Food & Beverage$1,028 (95.5%)
Education$48.12 (4.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,028 | 50 | 95.5% |
| Education | $48.12 | 2 | 4.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $211.88 | 10 | $0 (2024) |
| Theravance Biopharma Inc. | $156.65 | 10 | $0 (2017) |
| Merck Sharp & Dohme LLC | $126.32 | 6 | $0 (2024) |
| ViiV Healthcare Company | $117.21 | 6 | $0 (2021) |
| CARDIVA MEDICAL, INC. | $92.63 | 1 | $0 (2023) |
| Cumberland Pharmaceuticals, Inc. | $81.78 | 3 | $0 (2023) |
| Janssen Biotech, Inc. | $75.75 | 4 | $0 (2021) |
| ABBVIE INC. | $62.07 | 3 | $0 (2024) |
| Melinta Therapeutics, LLC | $50.30 | 2 | $0 (2024) |
| Allergan, Inc. | $43.65 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156.03 | 6 | Merck Sharp & Dohme LLC ($59.32) |
| 2023 | $196.93 | 5 | CARDIVA MEDICAL, INC. ($92.63) |
| 2022 | $97.91 | 5 | Gilead Sciences, Inc. ($48.63) |
| 2021 | $240.38 | 11 | Gilead Sciences, Inc. ($84.69) |
| 2020 | $43.65 | 3 | Allergan, Inc. ($43.65) |
| 2019 | $14.10 | 1 | ViiV Healthcare Company ($14.10) |
| 2018 | $92.73 | 6 | Gilead Sciences, Inc. ($31.45) |
| 2017 | $234.80 | 15 | Theravance Biopharma Inc. ($156.65) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/18/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: ANTIFUNGALS | ||||||
| 08/13/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/02/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/29/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO, DIFICID | Food and Beverage | In-kind items and services | $34.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.87 | General |
| 12/15/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: ANTIFUNGALS | ||||||
| 12/14/2023 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Education | In-kind items and services | $44.99 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 10/18/2023 | CARDIVA MEDICAL, INC. | CARDIVA VASCADE 6/7F VCS (Device) | Food and Beverage | In-kind items and services | $92.63 | General |
| Category: DEVICES | ||||||
| 08/23/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/04/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.24 | General |
| 09/22/2022 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 06/29/2022 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/03/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.77 | General |
| 02/23/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.86 | General |
| 02/01/2022 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 12/07/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.05 | General |
| 10/21/2021 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: HIV | ||||||
| 10/15/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: HIV | ||||||
| 10/11/2021 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 08/31/2021 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 08/10/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.05 | General |
| 07/14/2021 | Merck Sharp & Dohme Corporation | PIFELTRO (Drug), ISENTRESS, DIFICID | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/07/2021 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 06/23/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 726 | 1,150 | $366,635 | $105,631 |
| 2022 | 7 | 645 | 950 | $231,503 | $86,789 |
| 2021 | 8 | 722 | 1,111 | $246,270 | $101,273 |
| 2020 | 6 | 875 | 1,457 | $304,993 | $126,878 |
Total Patients
2,968
Total Services
4,668
Medicare Billing
$420,571
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 209 | 359 | $116,675 | $33,734 | 28.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 187 | 201 | $100,500 | $27,321 | 27.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 171 | 355 | $88,750 | $22,127 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 87 | 154 | $38,500 | $15,031 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 42 | $7,560 | $2,896 | 38.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $6,650 | $2,480 | 37.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $8,000 | $2,042 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 167 | 176 | $72,270 | $27,555 | 38.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 185 | 314 | $68,744 | $25,346 | 36.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 124 | 246 | $38,719 | $13,897 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 115 | $28,750 | $11,358 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 53 | 61 | $10,980 | $4,414 | 40.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $7,000 | $2,313 | 33.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $5,040 | $1,905 | 37.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 189 | 204 | $79,560 | $32,500 | 40.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 212 | 371 | $75,313 | $30,554 | 40.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 169 | 331 | $46,671 | $18,976 | 40.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 63 | 105 | $23,898 | $10,310 | 43.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 37 | 48 | $7,740 | $3,588 | 46.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 25 | 25 | $8,408 | $3,432 | 40.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 16 | 16 | $4,240 | $1,725 | 40.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 11 | 11 | $440.00 | $187.44 | 42.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 245 | 258 | $100,620 | $42,325 | 42.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 268 | 452 | $91,756 | $38,207 | 41.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 248 | 590 | $83,190 | $34,468 | 41.4% |
About Dr. Ameera Siddiqi, MD
Dr. Ameera Siddiqi, MD is a Infectious Disease healthcare provider based in Fayetteville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2010. The National Provider Identifier (NPI) number assigned to this provider is 1518283308.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ameera Siddiqi, MD has received a total of $1,077 in payments from pharmaceutical and medical device companies, with $156.03 received in 2024. These payments were reported across 52 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($1,028).
As a Medicare-enrolled provider, Siddiqi has provided services to 2,968 Medicare beneficiaries, totaling 4,668 services with total Medicare billing of $420,571. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Fayetteville, GA
- Active Since 04/19/2010
- Last Updated 02/14/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1518283308
Products in Payments
- VIBATIV (Drug) $221.47
- CARDIVA VASCADE 6/7F VCS (Device) $92.63
- DALVANCE (Drug) $62.43
- SYMTUZA (Drug) $61.80
- PIFELTRO (Drug) $57.42
- Rezzayo (Drug) $50.30
- TRIUMEQ (Drug) $33.22
- JULUCA (Drug) $31.43
- DOVATO (Drug) $28.41
- DIFICID (Drug) $27.46
- AVYCAZ (Drug) $25.34
- ZERBAXA (Drug) $24.45
- RUKOBIA (Drug) $24.15
- TEFLARO (Drug) $17.95
- XERAVA (Drug) $17.31
- Vibativ (Drug) $16.96
- ELIQUIS (Drug) $15.23
- HYQVIA (Biological) $14.25
- PREZISTA (Drug) $13.95
- CUVITRU (Biological) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Fayetteville
Dr. Chukwuemeka Chima, Md, MD
Infectious Disease — Payments: $47,564
Infectious Disease $47,564
Dr. James Newton, M.d, M.D
Infectious Disease — Payments: $30,570
Infectious Disease $30,570
Carlos Lewis, D.o, D.O
Infectious Disease — Payments: $6,035
Infectious Disease $6,035
Dr. Gweneth Francis, D.o, D.O
Infectious Disease — Payments: $3,820
Infectious Disease $3,820
Mukul Patharkar, M.d, M.D
Infectious Disease — Payments: $3,360
Infectious Disease $3,360
Dr. Renaldo Neeley, Md, MD
Infectious Disease — Payments: $1,865
Infectious Disease $1,865